Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer
Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.
Ämnen: Farmaci
-
-
Tagrisso significantly improves progression-free survival in the phase III FLAURA trial for lung cancer
AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment......
-
AstraZeneca reports initial results from the ongoing MYSTIC trial in stage IV lung cancer
AstraZeneca and MedImmune today announced progression-free survival (PFS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab versus platinum-based standard-of-care (SoC) chemotherapy in previously-untreated patients with metastatic (Stage IV) 1st-line non-small cell lung cancer
-
AstraZeneca and Merck establish strategic oncology collaboration
AstraZeneca and Merck & Co., Inc., today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
-
AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2017
Pascal Soriot, koncernchef, kommenterar resultatet:
”Vårt resultat för första halvåret var i linje med förväntningarna eftersom vi påverkades av effekterna av patentutgången för Crestor och Seroquel XR i USA. Vi fortsatte att leverera nyskapande forskning inom alla våra forskningsområden, i synnerhet inom onkologi. Imfinzi lanserades mot cancer i urinblåsan, samtidigt som vi publicerade banbryt -
Faslodex receives EU approval as first-line therapy for advanced breast cancer
AstraZeneca today announced that the European Commission (EC) has approved Faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.
-
Upptäckter som räddar liv – årets tema för Sommarforskarskolan
Måndag 31 juli öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på Göteborgs universitet.
-
KYNTHEUM APPROVED IN THE EU FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Kyntheum is the first and only fully-human monoclonal antibody that selectively targets the IL-17 receptor subunit A on skin cells.
-
Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorisation of Faslodex.
-
Upptäckter som räddar liv – årets tema för Sommarforskarskolan
Måndag 19 juni öppnas portarna till årets upplaga av AstraZenecas sommarforskarskola och de kommande två veckorna kommer 52 elever i åldrarna 14–17 år få testa på inspirerande och lärorika experiment i laboratoriesalarna på KTH i Stockholm.
-
Nordisk registerstudie på ADA: Behandling av typ 2-diabetes med SGLT-2-hämmare, jämfört med andra glukossänkande läkemedel, förknippas med en minskad risk för förtida död och hjärtsvikt
Resultat från den nordiska delen av observationsstudien CVD-REAL, presenterades vid ADA, den 11 juni. Resultaten visar att behandling av typ 2-diabetes med SGLT2-hämmare i klinisk verklighet är associerad med en signifikant minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.
-
AstraZeneca presents new data underpinning safety profile and Real-World CV outcomes of Farxiga at ADA 2017
Comprehensive updated analysis provides valuable evidence on the safety profile of Farxiga, including no imbalance in lower-limb amputations New analyses from CVD-REAL examine reductions in CV events for SGLT-2 inhibitors, including Farxiga in patients with and without CV disease versus DPP-4 inhibitors
-
AstraZeneca to present scientific advances in Cardiovascular and Metabolic Diseases at 2017 ADA Scientific Sessions
AstraZeneca and its global biologics research and development arm, MedImmune, will present the latest research from the Company’s Cardiovascular and Metabolic Diseases (CVMD) therapy area, including for Farxiga (dapagliflozin) and Bydureon(exenatide extended-release), with more than 50 abstracts at the American Diabetes Association’s (ADA) 77th Scientific Sessions in San Diego, USA, 9-13 June 2017
-
AstraZeneca enters agreement with Grünenthal to divest rights to migraine treatment Zomig
AstraZeneca today announced that it has entered an agreement with Grünenthal for the global rights to Zomig(zolmitriptan) outside Japan
-
Lynparza significantly reduces the risk of disease worsening or death in patients with BRCA-mutated metastatic breast cancer
AstraZeneca today presented positive results from its Phase III OlympiAD trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for patients treated with Lynparza (olaparib) tablets (300mg twice daily), compared to treatment with physician’s choiceof a standard of care chemotherapy.
-
AstraZeneca delivers new data on expanding portfolio of cancer medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
AstraZeneca, along with its global biologics research and development arm, MedImmune, will demonstrate how it is rapidly delivering on the Company’s science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk
AstraZeneca today announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial.
-
Phase III Zonda trial for benralizumab shows ability to reduce oral steroid use in severe asthma patients
Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to significantly reduce or discontinue steroids while maintaining asthma control.
-
AstraZeneca enters agreement with Recordati for Seloken in Europe
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK
-
AstraZeneca to present scientific advancements from growing respiratory portfolio at the American Thoracic Society conference 2017
AstraZeneca and its global biologics research and development arm, MedImmune, will present new data from its growing respiratory portfolio and pipeline at the 113th annual conference of the American Thoracic Society (ATS) in Washington, DC, USA, 19-24 May 2017
Visa mer
Loading...